Summary:
In patients with diabetic foot ulcers (DFUs), Wharton’s jelly mesenchymal stem cell-derived exosomes (MSC-Exos) significantly improved wound healing outcomes compared to standard wound care management, though it was associated with minimal adverse effects, which were generally well-tolerated.
| PICO | Description |
|---|---|
| Population | Patients diagnosed with diabetic foot ulcers (DFUs) requiring advanced wound healing interventions. |
| Intervention | Application of Wharton’s jelly mesenchymal stem cell-derived exosomes (MSC-Exos) as a novel biological treatment promoting wound repair. |
| Comparison | Standard wound care regimens without MSC-Exos, including conventional dressings and routine management practices. |
| Outcome | MSC-Exos significantly enhanced wound closure rates and accelerated healing time compared to standard care. Treatment was well tolerated with minimal reported side effects, demonstrating its safety and efficacy in DFU management. |
Source: Mohamed S Kishta, et al. “The transforming role of Wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial.” Read article here.
